These findings are consistent with previous reports showing increasing G6PD activity with cancer progression and decreased levels after treatment, suggesting that serum G6PD activity reflects tumor burden and could be clinically useful for disease staging and monitoring in gastric cancer. This evidence concerns the gene G6PD and gastric cancer.